GlassScriptPhysician profile
Bhargavi Patel
NPI 1417203928
$3,062.73
in general payments reported to CMS, 2019-2025
25 companies · $1,139 in 2025
The $1,139 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $265 · 2023: $569 · 2024: $886 · 2025: $1,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,184.88 |
| Education | $408.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $862.65 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $327.14 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $231.04 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Sanofi-Aventis U.S. LLC | $199.98 | 2023-2025 | |
| Lilly USA, LLC | $177.84 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $153.11 | 2022-2025 | Opzelura |
| Genzyme Corporation | $139.57 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2023 | Tezspire |
| Amgen INC. | $107.87 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $104.75 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $97.78 | 2024-2025 | Cabtreo, Jublia, Duobrii |
| Galderma Laboratories, L.P. | $84.17 | 2024-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $76.86 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $72.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.60 | 2023-2025 | Spevigo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $45.29 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $37.79 | 2023-2024 | |
| Ucb, INC. | $33.48 | 2025 | Bimzelx |
| Paratek Pharmaceuticals, INC. | $30.24 | 2021-2025 | Nuzyra |
| Leo Pharma INC. | $30.01 | 2025 | Anzupgo |
| Botanix Sb INC | $17.54 | 2025 | Sofdra |
| Glaxosmithkline, LLC. | $16.64 | 2023 | Shingrix |
| Dexcom, INC. | $16.36 | 2022 | |
| Almirall LLC | $15.55 | 2021 | |
| Medtronic, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhargavi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.